Changes in the survival of older patients with hematologic malignancies in the early 21st century

Cancer

Volumn 122, Issue 13, 2016, Pages 2031-2040

  Pulte, Dianne ^a,b   Jansen, Lina ^a   Castro, Felipe A ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

disparities; hematologic malignancies; older patients; population based analysis; survival

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLACK PERSON; CANCER SURVIVAL; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL RATE; CANCER REGISTRY; EPIDEMIOLOGY; HEMATOLOGIC DISEASE; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HEMATOLOGIC NEOPLASMS; HUMANS; MIDDLE AGED; SEER PROGRAM; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 84966600747     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30003     Document Type: Article

References (41)

1. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–1411.
2. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594–600.
3. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168:469–476.
4. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008;93:1544–1549.
5. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111:4916–4921.
6. Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;119:990–996.
7. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–1999.
8. Sant M, Minicozzi P, Mounier M, et al. Survival for haematologic malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population based study. Lancet Oncol. 2014;15:931–942.
9. Pulte D, Gondos A, Brenner H. Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008–12. Cancer Epidemiol. 2012;36:e19–e25.
10. Redaniel MT, Pulte D, Jeffreys M. Survival disparities by age and country of diagnosis for patients with acute leukemia. Leuk Lymphoma. 2015;6:1–6.
11. Rousselot P, Cony-Makhoul P, Nicolini F, et al. Long-term safety and efficacy of imatinib mesylate in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. Am J Hematol. 2013;88:1–4.
12. Proetel U, Pletsch N, Lauseker M, et al. Older patients with chronic myeloid leukemia profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol. 2014;93:1167–1176.
13. Coiffer B, LePage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–242.
14. Michallet AS, Cazin B, Bouvet E, et al. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. J Geriatr Oncol. 2013;4:141–147.
15. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429–435.
16. Hoglund M, Sandlin F, Hellstrom K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from population-based Swedish CML registry. Blood. 2013;122:1284–1292.
17. Surveillance, Epidemiology, and End Results Program. Research data (1973–2012), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission. http://seer.cancer.gov/.
18. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78:2004–2010.
19. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Bethesda, MD: National Cancer Institute; 1959.
20. Arias E. United States life tables, 2000. Natl Vital Stat Rep. 2002;51:1–38.
21. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164:689–696.
22. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patients survival. Eur J Cancer. 2002;38:690–695.
23. Dinmohamed AG, Visser O, van Norden Y, et al. Treatment, trial participation, and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. Leukemia. 2016;30:24–31.
24. Medeiros BC, Saram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94:1127–1138.
25. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916–1924.
26. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk. 2011;11(suppl 1):S54–S59.
27. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–1887.
28. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.
29. Rijneveld AW, van der Holt B, Daenen SM, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogenic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25:1697–1703.
30. Dinmohamed AG, Szabo A, van der Mark M, et al. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016;30:310–317.
31. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652.
32. Menzin J, Lang K, Earle CC, Glendenning A. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukemia: a population-based analysis. Drugs Aging. 2004;21:737–746.
33. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
34. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16:1600–1603.
35. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–5506.
36. Pulte D, Jansen L, Gondos A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol. 2014;164:851–857.
37. Pulte D, Redaniel MT, Brenner H, Jeffreys M. Changes in survival by ethnicity of patients with cancer between 1992-1996 and 2002-2006: is the discrepancy decreasing? Ann Oncol. 2012;23:2428–2434.
38. Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol. 2009;33:337–346.
39. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–1251.
40. Pulte D, Jansen L, Brenner H. Survival disparities by insurance type for patients aged 15-64 with non-Hodgkin lymphoma. Oncologist. 2015;20:554–561.
41. Robinson D, Sankila R, Hakulinen T, Moeller H. Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only case on survival estimates. Eur J Cancer. 2007;43:909–913.